Reserve Meds vs. everyone.org: a comparison.

Families and prescribers comparing cross-border specialty-access coordinators sometimes ask us directly how we differ from everyone.org, the longest-established patient-facing named-patient program facilitator in the European market. The fair answer is that we are different businesses doing overlapping work, we are right for different situations, and a thoughtful family or prescriber should choose the coordinator whose model fits the case rather than assume either of us is universally preferable. This page is our attempt at an honest side-by-side, written without disparagement.

everyone.org in brief

everyone.org is a named-patient program facilitator based in Europe, with established operations across a wide set of European destinations and significant experience coordinating cross-border access for European patients who cannot obtain a specific therapy in their country of residence. Their model is predominantly business-to-consumer, with a web-first intake and a global network of licensed pharmacies across jurisdictions. They have been operating for many years, they serve a genuine need, and they have treated a large number of patients. Nothing on this page should be read as questioning the legitimacy or the track record of what they do.

Reserve Meds in brief

Reserve Meds is a brand operated by Altima Care, a US-licensed specialty wholesaler. We coordinate cross-border access specifically from the US supply chain into a defined set of destination countries, with a front-line concentration in the United Arab Emirates, the Kingdom of Saudi Arabia, India, Pakistan, and Egypt. Our supply chain is DSCSA-serialized from US specialty wholesalers through to handoff to destination importer of record. Our service is positioned as a luxury-concierge tier: cash-pay, prepay, a dedicated case-coordination lead, and an editorial-grade documentation package on every case.

How the two models differ

The first difference is the origin of the supply. everyone.org's model is global and flexible in where a therapy is sourced from, consistent with the European multi-jurisdictional pharmacy network they operate; our model is deliberately single-origin, US-sourced through the DSCSA chain, because that is the supply chain our regulatory posture is built around and the one we think is the right fit for a luxury-tier service. The second difference is service tier. everyone.org operates at a mass-market price point that reflects a broad addressable patient base and a lean cost-to-serve; we operate at a concierge tier that includes dedicated coordination, an on-site pharmacist-in-charge relationship, and an extended follow-up cycle, with the corresponding cost structure. The third difference is geographic focus. everyone.org's base is European patients and their destinations are global but concentrated in the European orbit; our base is Gulf and South Asian patients, our destinations are concentrated there, and our logistics capabilities are tuned to that footprint. The fourth difference is commercial orientation. everyone.org operates at consumer scale with a typical retail transaction shape; we operate at private-banking scale with a typical concierge-engagement shape, including longer intake conversations, more extensive documentation, and a slower commercial cadence.

Who each is right for

A European patient seeking access to a therapy their home country does not supply, with a modest administrative burden and a competitive price point, will likely be well served by everyone.org. A patient in the Gulf, in India, or in the countries our map covers, who is paying privately at a specialty tier, who values a dedicated coordinator and an extended service envelope, and whose prescriber would benefit from a US-anchored supply chain, will likely be well served by us. A patient in neither orbit may be better served by a local coordinator in the destination country, and we are happy to point toward reasonable options where we know them. Nothing about this page is a reason to avoid everyone.org; the reason to choose us over them is the specific fit between our model and the situation the patient is in.

Our differentiators, stated plainly

The DSCSA US supply chain is the most technically load-bearing of our differentiators. Every unit we coordinate is serialized at package level under US federal law, is traceable from manufacturer to patient, and passes through US-licensed specialty wholesale channels. For prescribers who are evaluating chain-of-custody risk as part of their professional decision-making, this posture matters, and it is distinct from what a multi-origin network can offer structurally. The luxury-concierge service tier is the second. A Reserve Meds engagement is closer in feel to a private-banking or concierge-medicine relationship than to a retail transaction, and that fit matters for the families we typically serve. The Gulf-and-India geographic focus is the third. We are built for the countries where our patients live, with local broker relationships, local regulatory intelligence, and local logistics experience that a generalist cannot replicate without equivalent investment.

Honest limits

We are a narrower service than everyone.org and we do not try to hide that. We do not operate into every country; we do not source outside the US; we do not work at a mass-market price point; and we decline cases that fall outside our clinical, regulatory, or sourcing posture. A family whose needs fall outside our lane should not choose us; a family whose needs fall inside our lane is unlikely to find a better coordinator for the specific shape of their case.

How to decide

For a family actively comparing, the practical step is to have a short conversation with both organizations. Ask each of the same questions about the specific case: where the supply will originate, what chain-of-custody documentation will travel with the unit, what the total cost will look like with line items, what the timeline will be for a case like yours, and what the service envelope looks like after the unit arrives. The comparison will usually be clear on the answers. For our side, the entry point is the self-screening walkthrough and then a consultation. For everyone.org, their own website offers the equivalent entry point.

A note on the category itself

Cross-border specialty access is a young category that is still evolving, and the coordinators that survive the next five years will be the ones that treat chain-of-custody, pharmacovigilance, and pricing transparency as non-negotiable. Our view is that the category will converge toward this standard; in the meantime, families are better served by coordinators that operate at the standard today. We think everyone.org's track record and our own operating posture each contribute to that convergence in different parts of the market, and we would rather see the standard rise than win by attacking a legitimate peer.

Reviewed 2026-04-22 by Reserve Meds’s AI clinical and regulatory review agents. Human pharmacist-in-charge: Altima Care. Next scheduled review: 2026-10-22.